Feasibility, acceptability and appropriateness of a reproductive patient reported outcome measure for cancer survivors.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
04
2021
accepted:
04
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Cancer patients can experience a number of reproductive complications as a result of cancer treatment and may benefit from reproductive preventative health strategies. A Reproductive Survivorship Patient Reported Outcome Measure (RS-PROM) is not currently available but could assist patients address reproductive concerns. To develop and test the acceptability, feasibility and appropriateness of a RS-PROM tool to be used to assess reproductive needs of cancer survivors aged 18-45 years. We reviewed the outcomes of a recently published audit of reproductive care provided in our cancer survivorship clinic to identify gaps in current service provided and used this along with available validated reproductive measures, to develop this pilot RS-PROM. Survivors aged 18-45 years either attending the SCH survivorship clinic over a 1-year period or participants on the Australasian Oncofertility Registry (AOFR) who had agreed to be contacted for future research studies were asked to complete the RS-PROM and a questionnaire on the acceptability, feasibility and appropriateness of content included. One-hundred and fifty patients participated (61.3% females). Median age at cancer diagnosis was 24.5 years (range: 2-45 years). Eighty percent of participants reported the length of the RS-PROM was "just right", 92% agreed they would not mind completing the RS-PROM and 92.7% were willing to answer all questions, with 97% agreeing that the RS-PROM would be an important tool in addressing difficult sexual/reproductive topics concerning with healthcare professionals. The large majority of survivors participating in our pilot study found the RS-PROM to be an acceptable, feasible and useful tool to assist discussions of their sexual and reproductive health concerns and experiences with their clinical team.
Sections du résumé
BACKGROUND
Cancer patients can experience a number of reproductive complications as a result of cancer treatment and may benefit from reproductive preventative health strategies. A Reproductive Survivorship Patient Reported Outcome Measure (RS-PROM) is not currently available but could assist patients address reproductive concerns.
PURPOSE
To develop and test the acceptability, feasibility and appropriateness of a RS-PROM tool to be used to assess reproductive needs of cancer survivors aged 18-45 years.
METHODS
We reviewed the outcomes of a recently published audit of reproductive care provided in our cancer survivorship clinic to identify gaps in current service provided and used this along with available validated reproductive measures, to develop this pilot RS-PROM. Survivors aged 18-45 years either attending the SCH survivorship clinic over a 1-year period or participants on the Australasian Oncofertility Registry (AOFR) who had agreed to be contacted for future research studies were asked to complete the RS-PROM and a questionnaire on the acceptability, feasibility and appropriateness of content included.
RESULTS
One-hundred and fifty patients participated (61.3% females). Median age at cancer diagnosis was 24.5 years (range: 2-45 years). Eighty percent of participants reported the length of the RS-PROM was "just right", 92% agreed they would not mind completing the RS-PROM and 92.7% were willing to answer all questions, with 97% agreeing that the RS-PROM would be an important tool in addressing difficult sexual/reproductive topics concerning with healthcare professionals.
CONCLUSION
The large majority of survivors participating in our pilot study found the RS-PROM to be an acceptable, feasible and useful tool to assist discussions of their sexual and reproductive health concerns and experiences with their clinical team.
Identifiants
pubmed: 34449779
doi: 10.1371/journal.pone.0256497
pii: PONE-D-21-14078
pmc: PMC8396734
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0256497Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Pediatr Blood Cancer. 2016 Sep;63(9):1622-8
pubmed: 27163396
Pediatr Blood Cancer. 2018 Nov;65(11):e27297
pubmed: 29972282
J Clin Oncol. 2018 Jul 20;36(21):2169-2180
pubmed: 29874135
Int J Cancer. 2017 Dec 1;141(11):2187-2196
pubmed: 28836277
Hum Reprod. 2018 Jul 1;33(7):1281-1290
pubmed: 29912328
J Natl Compr Canc Netw. 2017 Sep;15(9):1140-1163
pubmed: 28874599
Hum Reprod. 2008 Jan;23(1):178-86
pubmed: 18024486
Psychooncology. 2010 Feb;19(2):125-33
pubmed: 19296462
Qual Life Res. 2015 Jul;24(7):1629-33
pubmed: 25555836
J Surg Oncol. 2010 May 1;101(6):534-42
pubmed: 20401921
J Clin Oncol. 2016 Oct 1;34(28):3440-50
pubmed: 27458300
BMJ. 2010 Jan 18;340:c186
pubmed: 20083546
Clin Ther. 2020 Jan;42(1):25-33
pubmed: 31932079
J Adolesc Young Adult Oncol. 2016 Sep;5(3):215-25
pubmed: 26981848
J Clin Oncol. 2009 Jun 1;27(16):2677-85
pubmed: 19364965
J Clin Oncol. 2017 May 10;35(14):1577-1583
pubmed: 28350518
Psychooncology. 2019 Jan;28(1):22-30
pubmed: 30460732
Psychooncology. 2010 Feb;19(2):134-40
pubmed: 19296461
Lancet Oncol. 2016 May;17(5):567-76
pubmed: 27020005
J Clin Oncol. 2018 Jul 20;36(21):2160-2168
pubmed: 29874140
Psychooncology. 2018 Feb;27(2):401-409
pubmed: 28734119
Breast Cancer Res Treat. 2021 Apr;186(3):705-713
pubmed: 33452553
Pediatr Blood Cancer. 2012 Apr;58(4):621-6
pubmed: 21910212
Gynecol Oncol. 2018 Feb;148(2):403-413
pubmed: 29150143
Hum Reprod Update. 2019 Mar 1;25(2):159-179
pubmed: 30462263
J Cancer Surviv. 2014 Jun;8(2):218-28
pubmed: 24352870
Br J Haematol. 2014 Feb;164(4):526-35
pubmed: 24236665
Qual Life Res. 2017 Jul;26(7):1659-1672
pubmed: 28251543
Br J Cancer. 2005 Jul 25;93(2):200-7
pubmed: 15999104
J Adolesc Young Adult Oncol. 2021 Apr;10(2):131-141
pubmed: 33180653
Int J Cancer. 2008 Dec 15;123(12):2891-8
pubmed: 18798259